Nordea Investment Management AB Has $54.88 Million Position in Solventum Corporation $SOLV

Nordea Investment Management AB raised its stake in shares of Solventum Corporation (NYSE:SOLV) by 3.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 758,847 shares of the company’s stock after purchasing an additional 25,987 shares during the period. Nordea Investment Management AB owned 0.44% of Solventum worth $54,880,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. CYBER HORNET ETFs LLC bought a new stake in shares of Solventum during the 2nd quarter worth $28,000. Barrett & Company Inc. raised its holdings in Solventum by 206.2% in the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after acquiring an additional 268 shares during the period. IMG Wealth Management Inc. acquired a new position in Solventum during the 2nd quarter worth $31,000. MUFG Securities EMEA plc bought a new stake in Solventum during the second quarter valued at about $31,000. Finally, State of Wyoming acquired a new stake in shares of Solventum in the second quarter valued at about $33,000.

Analyst Ratings Changes

Several analysts recently weighed in on SOLV shares. BTIG Research upgraded Solventum from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Tuesday, December 2nd. UBS Group restated a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a report on Thursday, October 30th. Stifel Nicolaus boosted their price objective on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, Wall Street Zen raised shares of Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Five equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $88.64.

Solventum Stock Performance

NYSE:SOLV opened at $80.00 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 1.03. The firm has a 50-day moving average price of $80.65 and a 200 day moving average price of $75.58. The firm has a market capitalization of $13.88 billion, a PE ratio of 9.22, a price-to-earnings-growth ratio of 7.96 and a beta of 0.34. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $88.20.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. The business had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.Solventum’s quarterly revenue was up .7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Research analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its Board of Directors has initiated a share repurchase program on Thursday, November 20th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to buy up to 7.5% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its stock is undervalued.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.